MedPath

Lepirudin

Generic Name
Lepirudin
Drug Type
Biotech
CAS Number
138068-37-8
Unique Ingredient Identifier
Y43GF64R34
Background

Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. Natural hirudin is an endogenous anticoagulant found in Hirudo medicinalis leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).

Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications. HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.

Indication

Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with aspirin. Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.

Associated Therapies
Anticoagulation

Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis

Phase 4
Recruiting
Conditions
Prophylaxis of Deep Vein Thrombosis
Interventions
First Posted Date
2023-05-06
Last Posted Date
2023-05-06
Lead Sponsor
MinaPharm Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT05847205
Locations
🇪🇬

Alexandria University, Alexandria, Egypt

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

Completed
Conditions
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Interventions
First Posted Date
2011-02-25
Last Posted Date
2017-07-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
195
Registration Number
NCT01304238

Argatroban Versus Lepirudin in Critically Ill Patients

Phase 4
Terminated
Conditions
Heparin Induced Thrombocytopenia (HIT)
Interventions
First Posted Date
2008-11-26
Last Posted Date
2012-06-21
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Target Recruit Count
70
Registration Number
NCT00798525
Locations
🇩🇪

Universitätsklinikum Düsseldorf Klinik für Anästhesiologie, Düsseldorf, Germany

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

Phase 2
Completed
Conditions
Thrombosis
First Posted Date
2002-06-10
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
340
Registration Number
NCT00039767
Locations
🇺🇸

National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath